CAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

CAR-T Cell Therapy – Frederick Locke, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2018

Wednesday December 19, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Frederick Locke, MD, Program Co-Leader, Immunology, Moffitt Cancer Center discuss CAR-T clinical highlights from ASH 2018

Featured Videos

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

Arndt Vogel, MD, elaborates on the results of the CheckMate-459 study in HCC

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations